RECCE PHARMACEUTICALS LTD — AGM Information 2024

Sep 15, 2024

2024 Annual General Meeting

16 September 2024 – Sydney, Australia: Recce Pharmaceuticals Ltd ( ASX:RCE, FSE:R9Q ( Recce or the Company ), the company developing a new class of Synthetic Anti-Infectives, advises that its Annual General Meeting is scheduled for Wednesday, 6 November 2024, further details of which will be provided in the notice of meeting to be dispatched to shareholders in due course.

In accordance with Listing Rule 3.13.1, Listing Rule 14.3, and Clause 14.3 of the Company’s Constitution, the Company advises that the closing date for the receipt of director nominations is Tuesday, 24 September 2024.

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE , FSE: R9Q ) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE[®] 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE[®] 435 (R435) as an orally administered therapy for bacterial infections; and RECCE[®] 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s antiinfectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

==> picture [467 x 44] intentionally omitted <==